NEW YORK
--
Bexil Corporation (AMEX: BXL) announced today that it had received a notice of
failure to satisfy a continued listing standard from the American Stock Exchange
on April 20, 2005 relating to its obligation to file a Form 10-KSB for the
fiscal year ended December 31, 2004. The Exchange advised Bexil that the timely
filing of such reports is a condition for

the Bexil's
continued listing on the Exchange and that the failure to timely file a Form
10-KSB is a material violation of Bexil's listing agreement with the Exchange.

Previously, Bexil had announced that it had submitted a notification of late
filing on Form 12b-25 that it would make a late filing of its annual report on
Form 10-KSB for the year ended December 31, 2004 due to delays in concluding the
new client acceptance process with its new auditors. Bexil's Form 10-KSB
filing is currently expected by May 20, 2005.

In response to the notice, Bexil confirmed its receipt of the notice to the
Exchange and discussed developments with the Exchange staff. Bexil also
indicated that it intends to submit a plan of compliance to the Exchange by May
4, 2005, advising the Exchange of action it has taken, or will take, that would
bring Bexil into compliance by no later than June 15, 2005. The Exchange has
advised Bexil that the Listings Qualifications Department management will
evaluate the plan, including any supporting documentation, and make a
determination as to whether Bexil has made a reasonable demonstration in the
plan of an ability to regain compliance with all applicable continued listing
standards by June 15, 2005, in which case the plan will be accepted. The
Exchange has further advised Bexil that if the plan is accepted, Bexil will
remain listed during the plan period, during which time it will be subject to
periodic review to determine whether it is making progress consistent with the
plan.

This press release may contain "forward looking information" and
"forward looking statements" and similar expressions that reflect
Bexil's current expectations about its future performance, and are subject to
risks, uncertainties and other factors that could cause Bexil's actual
performance to differ materially from those expressed in, or implied by, the
forward looking information and these forward-looking statements.